Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors: An update after long-term follow-up from two centers of the European intergroup study EICESS

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1451-1462

  Burdach, S ^a   Van Kaick, B ^b   Laws, H J ^b   Ahrens, S ^c   Haase, R ^a   Korholz D ^d   Pape, H ^b   Dunst, J ^a   Kahn, T ^d   Willers, R ^b   Engel, B ^e   Dirksen, U ^b   Kramm, C ^b   Nurnberger W ^b   Heyll, A ^b   Ladenstein, R ^f   Gadner, H ^f   Jurgens H ^c   Gobel U ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Advanced Ewing tumors; Allogeneic stem cell transplantation; Autologous stem cell transplantation; IL 2 therapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DISEASE COURSE; EWING SARCOMA; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOTHERAPY; MALE; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0033635352     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026539908115     Document Type: Article

References (56)

1. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor prognosis Ewing sarcoma
2. High-dose busulphan/ melphalan with autologous stem-cell rescue in Ewing's sarcoma
3. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma
4. Place de la chimiotherapie a hautes doses suivie d'autogreffe medullaire dans le traitement des sarcomes d'Ewing metastatiques de l'enfant
5. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: A report from the EBMT solid tumour registry
6. Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies
7. The graft-versus-leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML)
8. Allogeneic vs. autologous stem-cell transplantation vs. chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study
9. Transplantation of hematopoietic stem cells. II: Indications for transplantation of hematopoietic stem cells after myeloablative therapy
10. Allogeneic and autologous transplantation for hematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification
11. Graft-versus-leukemia without graft-versus-host disease: An elusive goal of bone marrow transplantation
12. T cells, graft-versus-host disease and graft-versus-leukemia: Innovative approaches for blood and marrow transplantation
13. Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions
14. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
15. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience
16. The number needed to treat: A clinically useful nomogram in its proper context
17. Results of treatment of primary metastatic Ewing sarcoma. A retrospective analysis of 48 patients
18. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors
19. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management
20. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
21. Allogeneic bone marrow transplantation versus autologous stem-cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation
22. Evidence for a graftversus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
23. Allogenic bonemarrow transfusion suppresses development of lung metastases in osteogenic sarcoma patients after radical surgery
24. Graft-versus-myeloma effect: Proof of principle
25. Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma
26. Graft-versus-myeloma effect in two cases
27. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease
28. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation
29. Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma
30. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience
31. Nonparametric estimation from incomplete observations
32. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood
33. Allogeneic bone marrow transplantation in multiple myeloma
34. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
35. Outcome in 43 children presenting with metastatic Ewing sarcoma: The St. Jude Children's Research Hospital Experience, 1962-1992
36. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies
37. High-dose melphalan ± total body irradiation and autologous hematopoietic stem-cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor
38. Induction of a CD3+/ CD56+ lymphocyte population following gene-therapy with transgenic IL-2 secreting fibroblasts in a child with peripheral neuroectodermal malignancy
39. Immunstimulation durch interleukin-2 nach autologer stammzelltransplantation bei kindern und jugendlichen mit soliden tumoren (IL-2 therapy post autologous stem-cell transplantation stimulates the production of tumor cytotoxic cytokines in children and adolescents with solid tumors)
40. Combinatorial generation of variable fusion proteins in the Ewing family of tumours
41. Tumor translocation fusion protein transcrition factors as targets for cancer vaccines to induce cytotoxic T cells against pediatric sarcoma
42. Role of interleukin-2 in human hematological malignancies
43. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants
44. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2
45. Combined chemokine and cytokine gene transfer enhances antitumor immunity
46. Induction of two distinct NK-cell populations, activated T cells and antineoplastic cytokines, by IL-2 therapy in children with solid tumors
47. Second malignancies after treatment for Ewing's sarcoma: A report of the CESS-studies
48. EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) - Preliminary results
49. Ewing sarcoma-family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors
50. Malignant peripheral neuro-ectodermal tumours of childhood and adolescence
51. Incidence of second malignant neoplasms in children: Results of an international study
52. Bone sarcomas linked to radiotherapy and chemotherapy in children
53. Risk of second cancers after treatment for Hodgkin's disease
54. The incidence of secondary leukemias
55. Ewing's sarcoma. Radiographic pattern of healing and bony complications in patients with long-term survival
56. Risk of radiation-related subsequent malignant tumors in survivors of Ewing's sarcoma